Assuntos
Colágeno Tipo VII , Epidermólise Bolhosa Distrófica , Fibroblastos , Nanopartículas , Epidermólise Bolhosa Distrófica/genética , Epidermólise Bolhosa Distrófica/terapia , Epidermólise Bolhosa Distrófica/patologia , Epidermólise Bolhosa Distrófica/metabolismo , Colágeno Tipo VII/genética , Colágeno Tipo VII/metabolismo , Humanos , Fibroblastos/metabolismo , Terapia Genética/métodos , Células Cultivadas , Lipossomos , Lipídeos/químicaRESUMO
Patients living with inherited skin diseases have benefited from recent advances in DNA sequencing technologies that provide new or improved diagnostics. However, developing and delivering new treatments for the 'genodermatoses' remains challenging. The goal of creating topical preparations that can recover the inherent gene pathology remains largely aspirational. However, recent progress in two fields - the chemistry of topical delivery formulations (lipid nanoparticles) and the molecular biology of gene repair (CRISPR-Cas9, base and prime editing) - presents new opportunities to address this unmet need. In this review, we discuss how lipid nanoparticle delivery vehicles could be used to deliver gene-editing tools to formulate topical 'gene creams' suitable for the treatment of genodermatoses. We summarize the historical landscape of topical therapeutics and advances in gene editing that may herald an era of new therapies for patients with inherited skin disorders.